These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 3116203)

  • 21. Comparison of muscarinic receptor properties in hatched chick heart atrium and ventricle.
    Sorota S; Adam LP; Pappano AJ
    J Pharmacol Exp Ther; 1986 Mar; 236(3):602-9. PubMed ID: 3754007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine.
    Flynn DD; Mash DC
    J Pharmacol Exp Ther; 1989 Aug; 250(2):573-81. PubMed ID: 2760841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A unique regulatory profile and regional distribution of [3H]pirenzepine binding in the rat provide evidence for distinct M1 and M2 muscarinic receptor subtypes.
    Watson M; Yamamura HI; Roeske WR
    Life Sci; 1983 Jun; 32(26):3001-11. PubMed ID: 6688111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Agonist interactions with cardiac muscarinic receptors. Effects of Mg2+, guanine nucleotides, and monovalent cations.
    McMahon KK; Hosey MM
    Mol Pharmacol; 1985 Nov; 28(5):400-9. PubMed ID: 4058421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [3H]AF-DX 116 labels subsets of muscarinic cholinergic receptors in rat brain and heart.
    Wang JX; Roeske WR; Gulya K; Wang W; Yamamura HI
    Life Sci; 1987 Oct; 41(14):1751-60. PubMed ID: 3657382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Muscarinic cholinergic ligand binding to intact mouse pituitary tumor cells (AtT-20/D16-16) coupling with two biochemical effectors: adenylate cyclase and phosphatidylinositol turnover.
    Akiyama K; Vickroy TW; Watson M; Roeske WR; Reisine TD; Smith TL; Yamamura HI
    J Pharmacol Exp Ther; 1986 Mar; 236(3):653-61. PubMed ID: 3005550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tetrahydroaminoacridine and other allosteric antagonists of hippocampal M1 muscarine receptors.
    Potter LT; Ferrendelli CA; Hanchett HE; Hollifield MA; Lorenzi MV
    Mol Pharmacol; 1989 May; 35(5):652-60. PubMed ID: 2725474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence of paired M2 muscarinic receptors.
    Potter LT; Ballesteros LA; Bichajian LH; Ferrendelli CA; Fisher A; Hanchett HE; Zhang R
    Mol Pharmacol; 1991 Feb; 39(2):211-21. PubMed ID: 1899905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of muscarinic M4 binding sites in rabbit lung, chicken heart, and NG108-15 cells.
    Lazareno S; Buckley NJ; Roberts FF
    Mol Pharmacol; 1990 Dec; 38(6):805-15. PubMed ID: 2250662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pirenzepine distinguishes between muscarinic receptor-mediated phosphoinositide breakdown and inhibition of adenylate cyclase.
    Gil DW; Wolfe BB
    J Pharmacol Exp Ther; 1985 Mar; 232(3):608-16. PubMed ID: 2579230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different agonist-receptor active conformations for rat brain M1 and M2 muscarinic receptors that are separately coupled to two biochemical effector systems.
    McKinney M; Anderson D; Vella-Rountree L
    Mol Pharmacol; 1989 Jan; 35(1):39-47. PubMed ID: 2536467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological differences between the high-affinity muscarinic agonist binding states of the rat heart and cerebral cortex labeled with (+)-[3H]cismethyldioxolane.
    Vickroy TW; Roeske WR; Yamamura HI
    J Pharmacol Exp Ther; 1984 Jun; 229(3):747-55. PubMed ID: 6202869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholinergic innervation and topographical organization of muscarinic binding sites in rat brain: a comparative autoradiographic study.
    Tonnaer JA; Ernste BH; Wester J; Kelder K
    J Chem Neuroanat; 1988; 1(2):95-110. PubMed ID: 3267343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subtype-specific changes in ligand binding properties after solubilization of muscarinic receptors from baculovirus-infected Sf9 insect cell membranes.
    Rinken A
    J Pharmacol Exp Ther; 1995 Jan; 272(1):8-14. PubMed ID: 7815368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of muscarinic cholinergic receptor affinity for antagonists in rat heart.
    Martin MW; Smith MM; Harden TK
    J Pharmacol Exp Ther; 1984 Aug; 230(2):424-30. PubMed ID: 6379149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Muscarinic acetylcholine receptor-mediated phosphoinositide turnover in cultured cerebellar granule cells: desensitization by receptor agonists.
    Xu J; Chuang DM
    J Pharmacol Exp Ther; 1987 Jul; 242(1):238-44. PubMed ID: 3039110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphatidylinositol response to cholinergic agonists in airway smooth muscle: relationship to contraction and muscarinic receptor occupancy.
    Grandordy BM; Cuss FM; Sampson AS; Palmer JB; Barnes PJ
    J Pharmacol Exp Ther; 1986 Jul; 238(1):273-9. PubMed ID: 3014119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On the muscarinic receptors in the urinary bladder and the putative subclassification of muscarinic receptors.
    Nilvebrant L
    Acta Pharmacol Toxicol (Copenh); 1986; 59 Suppl 1():1-45. PubMed ID: 3524114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regional distribution of M1, M2 and non-M1, non-M2 subtypes of muscarinic binding sites in rat brain.
    Ehlert FJ; Tran LP
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1148-57. PubMed ID: 2262898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Solubilization and partial purification from mouse sperm membranes of the specific binding activity for 3-quinuclidinyl benzilate, a potent inhibitor of the zona pellucida-induced acrosome reaction.
    Ward CR; Kopf GS; Storey BT
    Mol Reprod Dev; 1994 Dec; 39(4):423-32. PubMed ID: 7893491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.